Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men
- 10 healthy men
- Single dose
- 100, 250 and 500 mg
- Dose-escalation
The first human trial of oral NMN. Single doses of up to 500 mg caused no adverse symptoms and no change in vital signs, and the compound was measurably metabolised. This was a safety and metabolism study — it was not designed to measure a benefit.




